An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH

Prior treatment

• Previous disability with pre-ICH mRS score ≥ 2;
• Previous use (within 1 month) of β-blockers or reserpine;

Other illness

• Infections within the last 4 weeks;
• Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;
• Brainstem hemorrhage;
• Severe or acute heart failure;
• Heart rate \< 65 beats/min;
• Known to be allergic to propranolol;
• Severe liver or renal insufficiency;
• History of malignant tumors;

Other

• Use of antibiotics within the last 2 weeks;
• Known pre-ICH dysphagia;
• Life expectancy less than 14 days;
• Death appeared imminent;
• Pregnancy or within 30 d of delivery;
• Bronchial asthma or COPD;
• Cardiogenic shock;
• Degree II-III atrioventricular blocks;
• Currently participating in other interventional clinical trials;
• Currently, immunosuppressants and immunotherapies are being administered.

• Patients aged \> 18 and ≤ 80 years of age;
• Can be treated with the study drug within 24 h of symptom onset;
• No fever or infection was observed upon admission;
• NIHSS score ≥10;
• Supratentorial parenchymal haematoma (≥10 mL);
• GCS score ≥ 6;
• Patients or their family members sign informed consent forms.